206 related articles for article (PubMed ID: 8804801)
1. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
4. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
5. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
6. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
[TBL] [Abstract][Full Text] [Related]
7. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; Spitzer WO; MacRae KD; Bruppacher R
Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
[TBL] [Abstract][Full Text] [Related]
8. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
Lidegaard O
Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
[TBL] [Abstract][Full Text] [Related]
9. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
10. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
12. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
13. The differential risk of oral contraceptives: the impact of full exposure history.
Lewis MA; MacRae KD; Kühl-Habichl D; Bruppacher R; Heinemann LA; Spitzer WO
Hum Reprod; 1999 Jun; 14(6):1493-9. PubMed ID: 10359554
[TBL] [Abstract][Full Text] [Related]
14. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
15. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
London RS
Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
[TBL] [Abstract][Full Text] [Related]
16. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Poulter NR; Chang CL; Farley TM; Marmot MG; Meirik O
Lancet; 1999 Jul; 354(9175):301-2. PubMed ID: 10440309
[TBL] [Abstract][Full Text] [Related]
17. Risk of venous thromboembolism with third-generation oral contraceptives: A review.
Weiss G
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 2):295-301. PubMed ID: 9988833
[TBL] [Abstract][Full Text] [Related]
18. Newer oral contraceptives and the risk of venous thromboembolism.
Walker AM
Contraception; 1998 Mar; 57(3):169-81. PubMed ID: 9617533
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives and venous thromboembolism: an epidemiological review.
Lidegaard O
Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
[TBL] [Abstract][Full Text] [Related]
20. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
Heinemann LA; Dinger JC; Assmann A; Minh TD
Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
